Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 3/20 | 0.39 |
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.39 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | APAF1 | O14727 | 2/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951587 | 0.90 | CA12 (0.38) | CA12CA1CA2CA9LMNA | |
| SCHEMBL29349737 | 0.70 | CA12 (0.63) | CA12CA1CA2CA9LMNA | |
| SCHEMBL29351462 | 0.70 | CA12 (0.63) | CA12CA1CA2CA9LMNA | |
| SCHEMBL1234749 | 0.70 | CA12 (0.63) | CA12CA1CA2CA9LMNA | |
| SCHEMBL1079927 | 0.70 | CA12 (0.63) | CA12CA1CA2CA9LMNA | |
| SCHEMBL1249654 | 0.69 | CA12 (0.55) | CA12CA1CA2CA9LMNA | |
| SCHEMBL11059706 | 0.68 | PRKDC (0.38) | LMNAHTTMAPTALDH1A1HPGD | |
| SCHEMBL10928532 | 0.68 | CA12 (0.59) | CA12CA1CA2CA9LMNA | |
| SCHEMBL8746483 | 0.68 | CA12 (0.59) | CA12CA1CA2CA9LMNA | |
| SCHEMBL10906238 | 0.67 | PRKDC (0.37) | LMNAHTTMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708660-B1 | POLYPEPTIDES | NOVOZYMES AS (DK) | 2026-04-29 | — | — | EP | disclosed |
| US-20260078359-A1 | POLYPEPTIDES | NOVOZYMES A/S (DK) | 2026-03-19 | — | — | US | disclosed |
| EP-4676920-A1 | PHOTOLABILE CYCLIC ACETALS AND KETALS FOR THE LIGHT-INDUCED DELIVERY OF ACTIVE ALDEHYDES AND KETONES | Firmenich SA (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20250313817-A1 | POLYPEPTIDES | NOVOZYMES A/S (DK) | 2025-10-09 | — | — | US | disclosed |
| EP-4426684-B1 | CYCLIC ACETALS AND KETALS FOR THE LIGHT-INDUCED RELEASE OF ACTIVE ALDEHYDES AND KETONES | FIRMENICH & CIE (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-3149143-B1 | USE OF POLYPEPTIDE | NOVOZYMES AS (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-12371682-B2 | Polypeptides | NOVOZYMES A/S (DK) | 2025-07-29 | — | — | US | disclosed |
| US-20250171717-A1 | DETERGENT COMPOSITIONS AND USES THEREOF | NOVOZYMES A/S (DK) | 2025-05-29 | — | — | US | disclosed |
| US-12264295-B2 | Encapsulated pro-perfume compounds | FIRMENICH SA (CH) | 2025-04-01 | — | — | US | disclosed |
| US-12241045-B2 | Detergent compositions and uses thereof | NOVOZYMES A/S (DK) | 2025-03-04 | — | — | US | disclosed |
| WO-2012087792-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087785-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120156158-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-06-21 | — | — | US | disclosed |
| US-20120156156-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-06-21 | — | — | US | disclosed |
| US-20120156159-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-06-21 | — | — | US | disclosed |
| US-20120156161-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-06-21 | — | — | US | disclosed |
| US-20120156162-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-06-21 | — | — | US | disclosed |
| US-20120156157-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-06-21 | — | — | US | disclosed |
| US-20120156155-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-06-21 | — | — | US | disclosed |
| US-20120156160-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156160-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20120156162-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | APEH, HPD, HAGH | CA12 1608/4885CA1 949/4885CA2 571/4885 |
| US-20120156155-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20260078359-A1 | POLYPEPTIDES | IDUA, IDE, AGL | CA12 1779/4885CA1 1761/4885CA2 2212/4885 |
| US-20120156156-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20120156159-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20120156161-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20120156157-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20120156158-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.